Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on AstraZeneca to 13,000 GBp from 12,000 GBp and keeps a Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZN:
- Merck, AstraZeneca: FDA to extend PDUFA date for sNDA for LYNPARZA combo
- AstraZeneca’s anifrolumab receives FDA orphan designation
- AstraZeneca says Dato-DXd ‘continued to demonstrate encouraging responses’
- AstraZeneca’s Dato-DXd shows ‘durable efficacy’ in HER2-low patients
- Guardant Health announces collaboration with AstraZeneca